Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and safety of dupilumab in pediatric chronic spontaneous urticaria
2022-000260-22Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in chronic idiopathic urticaria (CIU), sponsored by Sanofi. Primary endpoint: Serum dupilumab concentration over time.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-000260-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000260-22.